- Home
- VRAX vs PYPD Comparison
VRAX vs PYPD Comparison
Compare VRAX & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- PYPD
- Stock Information
- Founded
- VRAX 2013
- PYPD 2008
- Country
- VRAX United Kingdom
- PYPD Israel
- Employees
- VRAX N/A
- PYPD N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PYPD Medical/Dental Instruments
- Sector
- VRAX Health Care
- PYPD Health Care
- Exchange
- VRAX Nasdaq
- PYPD Nasdaq
- Market Cap
- VRAX 17.2M
- PYPD 16.3M
- IPO Year
- VRAX 2022
- PYPD 2020
- Fundamental
- Price
- VRAX $2.80
- PYPD $3.38
- Analyst Decision
- VRAX
- PYPD Buy
- Analyst Count
- VRAX 0
- PYPD 2
- Target Price
- VRAX N/A
- PYPD $12.00
- AVG Volume (30 Days)
- VRAX 13.0M
- PYPD 4.9K
- Earning Date
- VRAX 11-06-2024
- PYPD 08-14-2024
- Dividend Yield
- VRAX N/A
- PYPD N/A
- EPS Growth
- VRAX N/A
- PYPD N/A
- EPS
- VRAX N/A
- PYPD N/A
- Revenue
- VRAX $156,419.00
- PYPD N/A
- Revenue This Year
- VRAX $5,169.18
- PYPD N/A
- Revenue Next Year
- VRAX $66.97
- PYPD N/A
- P/E Ratio
- VRAX N/A
- PYPD N/A
- Revenue Growth
- VRAX 1727.11
- PYPD N/A
- 52 Week Low
- VRAX $0.60
- PYPD $2.95
- 52 Week High
- VRAX $9.00
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- VRAX 46.62
- PYPD 45.81
- Support Level
- VRAX $2.40
- PYPD $3.14
- Resistance Level
- VRAX $3.26
- PYPD $3.70
- Average True Range (ATR)
- VRAX 0.75
- PYPD 0.10
- MACD
- VRAX -0.31
- PYPD -0.00
- Stochastic Oscillator
- VRAX 9.18
- PYPD 42.75
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.